Mood Disorders

Fremanezumab for Preventive Migraine Treatment in Patients With Major Depressive Disorder: Baseline Patient Characteristics in the Phase 4 UNITE Study

Abstract: Introduction: Major depressive disorder (MDD) is a common migraine comorbidity. Fremanezumab, a humanized monoclonal antibody selectively targeting calcitonin gene-related pepti...

Maggie Kane ;

Richard Lipton , MD;

01/19/2023

Safety and Efficacy of Zuranolone 50 mg and Need for Repeat Treatment Courses in the Open-label, Phase 3 SHORELINE Study of Adult Patients With Major Depressive Disorder

Abstract: Introduction Zuranolone is a neuroactive steroid and positive allosteric modulator of both synaptic and extrasynaptic GABAA receptors in clinical development as an oral, once-da...

Andrew J. Cutler , MD;

Ryan Coleman ;

01/19/2023

Assessing the Need for Repeat Treatment Courses with Zuranolone in Adult Patients With Major Depressive Disorder With Elevated Anxiety: An Analysis of the Open-Label, Phase 3 SHORELINE Study

Abstract: Introduction Zuranolone is an investigational neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an o...

Greg Mattingly , MD;

Ryan Coleman ;

01/19/2023

Perspectives on the Unmet Need in the Treatment of Major Depressive Disorder: Results From A Patient Survey

Abstract: Background: Major depressive disorder (MDD) is a common brain health disorder that affects at least 1 in 5 individuals in the United States (US) during their lifetime. Adults wi...

Ming-Yi Huang , PhD;

01/19/2023

Zuranolone in Major Depressive Disorder (MDD): Minimal Important Difference (MID) and Meaningful Change Threshold (MCT) on the 17-item Hamilton Rating Scale for Depression (HAMD-17)

Abstract: Objective: WATERFALL (Phase 3; NCT04442490), adult patients with moderate to severe MDD who received zuranolone 50mg vs placebo showed statistically significant improvement in d...

Ming-Yi Huang , PhD;

01/19/2023

Real-World Safety Profile of Esketamine Nasal Spray During the First 12 Treatment Sessions: An Analysis at 34 Months After Approval

Abstract: Purpose: To examine real-world esketamine nasal spray (ESK) treatment-emergent adverse events (TEAEs) of interest (i.e., sedation, dissociation, increased blood pressure [BP]) a...

Brianne Brown , PsyD;

Elizabeth Daloisio ;

01/19/2023

Clinical, Economic, and Humanistic Outcomes Associated With Obesity Among Adults With Bipolar I Disorder: Analysis of National Health and Wellness Survey Data

Abstract: Background: People living with bipolar I disorder (BD-I) have a higher risk of obesity than the general population. While outcomes associated with obesity are well documented in...

Michael Doane , PhD;

01/19/2023

Relationship Between Patient Characteristics, Patterns of Treatment, and Medication Adherence Among Individuals with Major Depressive Disorder

Abstract: Background: Major depressive disorder (MDD) is associated with elevated health care and societal cost, increased morbidity and mortality, and diminished quality of life. First l...

Charles Ruetsch , PhD;

01/19/2023

Treatment Patterns among Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine or Traditional Therapies in the United States

Abstract: BACKGROUND: Treatment patterns among adults with major depressive disorder with suicidal ideation or behavior (MDSI) started on esketamine or traditional therapies were describe...

Kruti Joshi , MPH, MD;

01/19/2023

Esketamine Use among Patients with Treatment-resistant Depression Initiating Esketamine and Completing Induction in the United States

Abstract: BACKGROUND: Access to esketamine therapy for treatment-resistant depression (TRD) is available only through certified treatment centers in the US. Therapy starts with induction ...

Kruti Joshi , MPH, MD;

01/19/2023